๐๐Immensely grateful for the generous support and guidance from Dr. Ann Marie Navar, @virani_md, @ericpetersonMD, and @dramitkhera ๐๐
And many thanks to @JAMAInternalMed for offering an avenue to share our findings
How does the move to PREVENT for ASCVD risk estimation affect aspirin useโ
๐https://t.co/Gz9TGiW6sp
1โฃ >80% eligible for 1ry prevention aspirin based on a PCE risk >10% would no longer be eligible w/ PREVENT
2โฃ Most current aspirin users don't qualify under either calculator
Here are my takeaways for the 7 most relevant and important #ESCCongress2025 for generalists
AQUATIC, HI-PRO, RETREAT-FRAIL, DIGIT-HF, DAN-RSV were most practicing changing
POTCAST was most contentious - not as billed
Do heart transplant patients always need invasive angio to screen for graft vasculopathyโ
๐https://t.co/JVR5PRa1VN
In this meta-analysis, CTA/PET had pretty respectable sensitivity/NPV for ruling out graft vasculopathy compared to a gold standard of invasive angiography.
NEW PAPER in @bmj_latest "Dealing with continuous variables and modelling non-linear associations in healthcare data: practical guide"
--> https://t.co/4YGRasQVrx
#methodologymatters
๐๐Incredibly thankful to @almallahmo and Dr. Al Rifai for their supervision & guidance on this; and to my brilliant colleague @MariaAlwan_ ๐๐
And thank you to @EHJCVIEiC for allowing us to share our findings!
1/4๐งต
In patients undergoing cardiac stress testing w/ PET, does rest flow matterโ
In an analysis of >8k patients, we find that it does, esp. in patients with a preserved EF.
Link๐: https://t.co/05Nxx0K95o
@almallahmo@MariaAlwan_@MyASNC@MethodistHosp@EHJCVIEiC
Patients with a normal-ish EF could be further stratified as being at a *truly* low-risk of events or at intermediate risk depending on their rest flow.
In contrast, patients with a depressed EF had a uniformly high rate of events regardless.
An incredible experience at #DDW2025! Privileged to share our work on #pancreaticcancer, Fatty Pancreas, and #colorectalcancer
With 3 oral presentations, and 3 poster presentations โ
Immensely grateful for the mentorship and support of Dr. @SriGaddamMD ๐๐ผ
New genetic analysis in 200k people over 14 years
โถ๏ธapoB + lp(a) best capture lipid-mediated CV risk
โถ๏ธLDL particle size adds no additional info when apoB is accounted for
https://t.co/Kv7sUxAcmv
Intensive LDL-C lowering with Evolocumab may lead to greater relative reduction in cardiovascular events in patients with autoimmune or inflammatory diseases. @AndreZimerman@bweber04@analaurakunzler
@rgiuglaino https://t.co/oYtX8Vbxqu
Just in time for #HRS2025โผ๏ธ
Excited to share our latest paper published in @AmericanHeartJ and honored to be first co-author with Dr. Bockus.
Looking forward to presenting our work in San Diego.
https://t.co/n3AsBU4bNw
@NazemAkoum@UWMedHeart